Filter Results:
(617)
Show Results For
- All HBS Web
(617)
- People (2)
- News (55)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Show Results For
- All HBS Web
(617)
- People (2)
- News (55)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
- 01 Jun 2016
- News
@Soldiers Field
diverse, outstanding future leaders and who will go on to make a real difference in the world.” Baker Library’s Historical Collections acquired a trove of archival materials from Genzyme, one of the world’s leading biotechnology firms. A... View Details
- July 1993
- Case
Genzyme Corporation: A Financing History
By: Timothy A. Luehrman and Andrew D. Regan
Genzyme Corp.'s financing history is unusual compared to most biotech companies. This case presents the sequence of financings employed by Genzyme, along with the product--market and corporate-development strategies adopted by Henri Termeer, Genzyme's CEO. As such, the... View Details
Keywords: History; Marketing Strategy; Financing and Loans; Business Strategy; Growth and Development Strategy; Biotechnology Industry
Luehrman, Timothy A., and Andrew D. Regan. "Genzyme Corporation: A Financing History." Harvard Business School Case 294-005, July 1993.
- July 2023
- Case
Moderna: Everything, Everywhere, All at Once
By: Satish Tadikonda, Shikhar Ghosh and William Marks
Coming out of the COVID-19 pandemic, Moderna was riding the successes of developing a vaccine in record time and helping stem the tide of the crisis. However, the company had grown at an incredible rate, more than doubled its number of employees, and had to put on hold... View Details
Keywords: Health Pandemics; Selection and Staffing; Growth Management; Management Succession; Retirement; Technological Innovation; Corporate Strategy; Biotechnology Industry
Tadikonda, Satish, Shikhar Ghosh, and William Marks. "Moderna: Everything, Everywhere, All at Once." Harvard Business School Case 824-021, July 2023.
- November 2016
- Case
QuintilesIMS: Biosimilar Marketing in England
By: John A. Quelch and Emily C. Boudreau
QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details
Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England
Quelch, John A., and Emily C. Boudreau. "QuintilesIMS: Biosimilar Marketing in England." Harvard Business School Case 517-054, November 2016.
- 2009
- Case
Innovamedica: Innovation in an Emerging Market
By: Roberto Charvel, Fernando Fabre and T. Putimahtama
Innovamedica was a medical start up with several state of the art devices such as a silicon substitute heart and other inventions. However, the founding scientist was struggling in attracting talent and fundraising and that had an impact on growth. View Details
Keywords: Biotech; Entrepreneurial Finance; Entrepreneurship; Start-up; Emergent Countries; Business Startups; Talent and Talent Management; Design; Corporate Entrepreneurship; Private Equity; Health Testing and Trials; Innovation and Invention; Managerial Roles; Biotechnology Industry; Latin America; North and Central America
Charvel, Roberto, Fernando Fabre, and T. Putimahtama. "Innovamedica: Innovation in an Emerging Market." Instituto Panamericano de Alta Dirección de Empresa (IPADE) Case (P)DGe-440, 2009.
- March 2012 (Revised October 2013)
- Supplement
Gene Patents (B)
By: Richard Hamermesh and Phillip Andrews
The case updates events since the Court's ruling against Myriad Genetics on March 29, 2010 and should be used in conjunction with Gene Patents (A). On July 29, 2011, a US Appeals Court reversed the prior ruling against Myriad. On September 16, 2011, the first major... View Details
Keywords: Courts and Trials; Patents; Genetics; Judgments; Investment; Biotechnology Industry; United States
Hamermesh, Richard, and Phillip Andrews. "Gene Patents (B)." Harvard Business School Supplement 812-130, March 2012. (Revised October 2013.)
- January 2010
- Supplement
Genzyme's CSR Dilemma: How to Play its HAND - video supplement
By: Tarun Khanna and Christopher A. Bartlett
Keywords: Biotechnology Industry
Khanna, Tarun, and Christopher A. Bartlett. "Genzyme's CSR Dilemma: How to Play its HAND - video supplement." Harvard Business School Video Supplement 910-801, January 2010.
- January 2010 (Revised November 2012)
- Teaching Note
Genzyme's CSR Dilemma: How to Play its HAND (TN)
Teaching Note for [910407]. View Details
- October 2009 (Revised August 2014)
- Case
Tengion: Bringing Regenerative Medicine to Life
By: Elie Ofek and Polly Ross Ribatt
Tengion is a young biotech company that is at the frontier of regenerative medicine—a nascent field that seeks to promote the creation of new cells and tissue to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. In late... View Details
Keywords: Decision Choices and Conditions; Financial Crisis; Entrepreneurship; Health Care and Treatment; Technological Innovation; Product Launch; Product Development; Research and Development; Biotechnology Industry; United States
Ofek, Elie, and Polly Ross Ribatt. "Tengion: Bringing Regenerative Medicine to Life." Harvard Business School Case 510-031, October 2009. (Revised August 2014.)
- February 2008 (Revised August 2008)
- Case
EXACT Sciences Corp.: Commercializing a Diagnostic Test
This case addresses the challenges of commercializing molecular diagnostics. Along the way, it explains the technology, payment system, and the measures used to assess the value of a diagnostic test. View Details
Keywords: Health Testing and Trials; Genetics; Science-Based Business; Commercialization; Biotechnology Industry
Herzlinger, Regina E. "EXACT Sciences Corp.: Commercializing a Diagnostic Test." Harvard Business School Case 308-090, February 2008. (Revised August 2008.)
- June 2004 (Revised November 2004)
- Case
Acorda Therapeutics: Rebuilding the Spinal Cord
Acorda is an early-stage life science start-up with a promising product that is close to reaching the market (Phase III clinical trials). The company is grappling with how to expand its portfolio of molecules to make the business more sustainable. It faces classic... View Details
Keywords: Decision Making; Science-Based Business; Health Testing and Trials; Business Startups; Product Development; Biotechnology Industry
Enriquez-Cabot, Juan, Jonathan West, Marina Kolesnik, and Fiona Murray. "Acorda Therapeutics: Rebuilding the Spinal Cord." Harvard Business School Case 604-014, June 2004. (Revised November 2004.)
- October 1997
- Case
Roslin Institute, The
By: Ray A. Goldberg and Tom Clay
Dr. Ian Willmut and the Roslin Institute have developed a revolutionary new technology--cloning. Now they are faced with some tough choices concerning going forward. How should they balance commercialization opportunities with societal concerns? View Details
Keywords: Decision Choices and Conditions; Independent Innovation and Invention; Social Issues; Commercialization; Biotechnology Industry
Goldberg, Ray A., and Tom Clay. "Roslin Institute, The." Harvard Business School Case 598-045, October 1997.
- November 1986
- Case
Amgen
By: Ray A. Goldberg
Keywords: Biotechnology Industry
Goldberg, Ray A. "Amgen." Harvard Business School Case 587-095, November 1986.
- March 2018 (Revised July 2018)
- Case
Greenlight Biosciences: In Search of Impact Investment
By: Michael Chu, Annelena Lobb and Joni Coughlin
Greenlight Biosciences, a biotech company, is in search of impact investment for its next round of financing. View Details
Keywords: Impact Investment; Investment; Environmental Sustainability; Financing and Loans; Biotechnology Industry
Chu, Michael, Annelena Lobb, and Joni Coughlin. "GreenLight Biosciences: In Search of Impact Investment." Harvard Business School Case 318-072, March 2018. (Revised July 2018.)
- 01 Apr 2000
- News
Porter's Paradox
decisive, enduring advantages, therefore, become unique local centers of innovation for the likes of mutual funds, venture capital, and biotechnology in Greater Boston or aircraft equipment and design, boat- and shipbuilding, and metal... View Details
- 13 Feb 2023
- News
Alumnus Gift Will Nurture Basic, Therapeutic Science
been a partner of the School for over two decades, and I am delighted to continue to support the HMS community in its important work by helping to modernize these landmark facilities to keep pace with therapeutics innovation." Bertarelli is a former View Details
- Web
Collection Highlights | Baker Library
in the financing of the transcontinental railroad and development of the electrical industry. Henri A. Termeer Papers Document the career of an entrepreneur and biotechnology executive known for leading Genzyme Corporation from 1983 to... View Details
- 01 Jun 2000
- News
Managing the Map
We are at the dawn of a new epoch in the world of science, one that will cast strong light on a unique corner of the biotechnology field known as genomics. The designation refers to the study of genes, those chemical building blocks of... View Details
Keywords: Peter K. Jacobs
- 01 Jun 2000
- News
Seeing the Light
Living in Los Angeles and working as a marketer for a global biotechnology firm, Jana Kirlin Brownell (MBA '83) saw her career path take an unexpected turn. More than once, her father had asked her to come home and take over the Kirlin... View Details
- 01 Dec 2006
- News
Faculty Books
reveal the mechanisms of advancement and speculate on what this means for the future of leadership selection and development. Science Business by Gary P. Pisano (HBS Press) Why has the biotechnology industry failed to perform to... View Details